1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation

California DTSC Selects Toluene In Nail Care For Potential Phase-Out

 
• By Lauren Nardella

The proposal under the state’s Safer Consumer Products regulation marks the ingredient for alternative analyses and potential replacement in nail-care products. California’s Department of Toxic Substances Control cites possible dangers to salon workers in particular, including nervous system, respiratory and developmental toxicity risks.

shutterstock: Ksanawo

Solvent toluene is coming under scrutiny in California, with the state’s Department of Toxic Substances Control proposing that nail products containing the chemical be assessed for possible alternatives under the Safer Consumer Products regulation.

In a DTSC discussion draft

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

US Fragrance Firms Should Identify Domestic, Non-Tariff Sources Now – Fragrance House CEO

Firms in the US facing tariff costs should identify US-based, non-tariff sources and lobby local government officials and DC when foreign-sourced ingredients cannot be substituted in the US.

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By Lauren Nardella

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.